Abnormal Cholesterol Test Results:
Your Complete Guide

This section provides detailed scientific context for health professionals and enthusiasts who want to understand the evidence behind our recommendations.

ApoB vs. LDL-C: What the Evidence Shows

The superiority of ApoB over LDL-C for cardiovascular risk prediction has been demonstrated consistently across multiple study designs: observational cohorts, Mendelian randomization analyses, and clinical trials.

Mendelian Randomization Evidence: Holmes et al. (2020) analyzed 441,016 UK Biobank participants and found that when adjusting for ApoB in multivariable MR models, the associations between LDL-C and triglycerides with coronary heart disease became null—while ApoB remained robustly associated. This suggests ApoB is the causal variable, not cholesterol content per se.

The Zuber et al. (2021) MR-Bayesian Model Averaging analysis assigned ApoB a marginal inclusion probability of 0.92 as the primary lipid determinant of cardiovascular disease—essentially confirming that ApoB "wins" when you ask which lipid measure is truly causal.

Clinical Relevance of Discordance: Approximately 8-23% of the population has discordant ApoB and LDL-C values. In these cases, cardiovascular risk tracks with ApoB, not LDL-C. The CARDIA study found that individuals with high ApoB but normal LDL-C had 55% greater coronary artery calcium (CAC) risk than concordant individuals. This discordance is especially common in insulin resistance, where the liver produces more small, dense LDL particles (high ApoB) that carry less cholesterol each (normal LDL-C).

Meta-analyses of 12 cohorts comprising over 100,000 participants show ApoB predicts ischemic events with a relative risk ratio of 1.43 per standard deviation increase, compared to 1.25 for LDL-C. In statin-treated patients (Copenhagen studies), ApoB predicts mortality better than LDL-C, which loses statistical significance.

Lp(a): The Independent Causal Risk Factor

Lipoprotein(a) is structurally an LDL particle with apolipoprotein(a) [apo(a)] covalently bound to ApoB-100 via a disulfide bond. This additional protein gives Lp(a) unique properties that make it approximately 5-6 times more atherogenic than LDL on an equimolar basis.

Genetic Determination: Unlike LDL, which responds substantially to diet and medications, Lp(a) levels are predominantly determined by the LPA gene locus. Mendelian randomization studies confirm causality: genetically determined doubling of Lp(a) increases MI risk by approximately 22%.

Oxidized Phospholipid Carriage: The critical insight about Lp(a) is its role as the primary carrier of oxidized phospholipids (OxPL) in human plasma—approximately 85% of OxPL precipitated by anti-ApoB antibodies associate with Lp(a). These OxPL drive inflammation through pattern recognition receptor activation, inducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and promoting monocyte trafficking to the arterial wall. Van der Valk et al. (Circulation 2016) demonstrated that subjects with elevated Lp(a) show increased arterial wall inflammation on PET imaging.

Therapeutic Implications: Statins do not lower Lp(a)—and may slightly increase it. Niacin and PCSK9 inhibitors provide modest (20-30%) reductions. New antisense oligonucleotide (pelacarsen) and siRNA (olpasiran) therapies achieve 80-90% Lp(a) reductions; cardiovascular outcomes trials are ongoing.

The TG/HDL Ratio as Insulin Resistance Proxy

Elevated triglycerides and low HDL-C are hallmarks of insulin resistance and metabolic syndrome. The TG/HDL ratio provides a simple, calculated metric that correlates well with HOMA-IR (a direct measure of insulin resistance) and with the presence of small, dense LDL particles.

In metabolic dysfunction, the liver overproduces VLDL (triglyceride-rich particles). As these particles lose triglycerides to tissues via lipoprotein lipase, they become smaller, denser LDL particles. This is why someone with insulin resistance can have "normal" LDL-C but elevated ApoB and high cardiovascular risk.

Thresholds: A TG/HDL ratio <0.9 (in mmol/L) suggests excellent insulin sensitivity. Ratios of 0.9-1.5 suggest developing insulin resistance. Ratios >1.5 indicate likely metabolic syndrome. Addressing the underlying insulin resistance—through carbohydrate restriction, exercise, weight loss, and potentially GLP-1 agonists—often improves the entire lipid profile more effectively than targeting LDL alone.

Inflammation Markers: hs-CRP and Beyond

The relationship between LDL and inflammation is neither confounded nor overlapping—the two pathways correlate at only r ≈ 0.08, representing largely independent mechanisms. Both contribute to cardiovascular risk, but their relative importance depends on treatment status.

In Treatment-Naïve Patients: Per-SD increases in hs-CRP produce risk magnitudes at least as large as per-SD cholesterol changes according to the Emerging Risk Factors Collaboration.

In Statin-Treated Patients: A 2023 Lancet analysis of 31,245 patients from PROMINENT, REDUCE-IT, and STRENGTH found that among patients on statin therapy, residual inflammatory risk (high vs. low hs-CRP quartile) predicted MACE with HR 1.31, while residual LDL-C risk showed no significant association. This suggests that in optimally LDL-treated patients, inflammation becomes the dominant residual risk factor.

The CANTOS trial (canakinumab, an anti-IL-1β antibody) proved inflammation's independent causal role: a 15% reduction in MACE was achieved without any change in LDL-C. Among responders achieving hs-CRP <2 mg/L, reductions reached 25% for MACE and 31% for cardiovascular mortality.

CAC Score: Strengths and Limitations

Coronary artery calcium scoring provides a direct visualization of atherosclerotic plaque burden. The "power of zero" refers to the excellent short-term prognosis of a CAC score of 0, even in patients with elevated LDL-C. The MESA study showed very low 10-year event rates in CAC=0 individuals.

However, limitations exist: CAC detects only calcified plaque, which represents more stable, late-stage disease. Soft plaque (lipid-rich, non-calcified)—often more vulnerable to rupture—is invisible on CAC scans. Additionally, CAC=0 doesn't guarantee freedom from future disease, especially in younger individuals or those with high Lp(a) who may develop calcified plaque later.

Long-term follow-up data show that even with CAC=0, elevated LDL predicts future development of CAC and cardiovascular events on a longer timeline. This underscores the importance of cumulative LDL exposure (area under the curve) over decades, not just point-in-time risk assessment.